DYNOMICS
We target therapeutics to human heart function, taking a precision approach to drug development and capturing the adult heart clinical phenotype. This is powered by our scalable, authentic and predictive discovery engine - HeartDyno. HeartDyno is built with engineered human cardiac organoids, scalably deployed to drive a multi-omics data-driven approach. It rapidly uncovers novel therapeutic targets and candidates that offer superior efficacy and safety profiles in humans. Dynomics’ approach is validated through collaboration with top pharmaceutical companies, top-tier scientific publications, and we are progressing assets targeting heart failure, affecting 4% of the US population and where current treatments provide a 50% 5-year survival rate.
DYNOMICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2020-01-01
Address:
San Mateo, California, United States
Country:
United States
Website Url:
http://www.dynomics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
500 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Global Site Tag
Similar Organizations
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Current Employees Featured
Founder
Investors List
Boost VC
Boost VC investment in Pre Seed Round - Dynomics
Official Site Inspections
http://www.dynomics.com Semrush global rank: 5.98 M Semrush visits lastest month: 1.37 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Dynomics"
Dynomics - Crunchbase Company Profile & Funding
Organization. Dynomics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Molecules to restore heart function. San Mateo, …See details»
Dynomics - Therapies to Restore Heart Function
Dynomics has developed a human-predictive discovery platform to power precision cardiac drug discovery. PLATFORM. Introducing HeartDyno & Tempo.ai. HeartDyno® is our cardiac …See details»
Dynomics Company Profile 2024: Valuation, Funding
Dynomics General Information Description. Developer of human cardiac organoids designed to target therapeutics to the heart and its functions directly. The company develops targeted treatments to eliminate heart failure using …See details»
Dynomics - The Org
Molecules to restore heart function. Access public org charts while browsing LinkedInSee details»
Dynomics - LinkedIn
Dynomics | 415 followers on LinkedIn. Targeted therapies to eliminate heart failure. | Heart failure affects 4% of the US population, yet treatment options are primarily symptomatic, including ...See details»
Dynomics Therapeutics - VentureRadar
Dynomics develops molecules to restore heart function. We’ve developed HeartDyno, our cardiac organoid discovery engine, using scalable, authentic and predictive cardiac organoids that …See details»
Dynomics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Oct 22, 2024 Explore Dynomics, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Dynomics - Contacts, Employees, Board Members, Advisors
Molecules to restore heart function.See details»
Dynomics - Products, Competitors, Financials, Employees, …
Dynomics specializes in the development of therapies in healthcare targeting heart failure. Use the CB Insights Platform to explore Dynomics's full profile. Dynomics - Products, Competitors, …See details»
Dynomics - Company Profile - Tracxn
Dynomics - Provider of human cardiac organoids to develop targeted therapies for heart failure. Raised funding from 3 investors. Dynomics has 66 competitors.See details»
Dynomics Inc. | CipherBio
Explore Dynomics Inc.'s investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Contact - dynomics.com
Decoding heart function to discover precision cardiac therapeutics. San Francisco, CA, United States of America Brisbane, QLD, AustraliaSee details»
James Hudson - Co-Founder at Dynomics - The Org
In 2020, they became a Co-Founder of Dynomics. James Hudson obtained a Doctor of Philosophy (PhD) in Biotechnology from The University of Queensland between 2007 and …See details»
Drew Titmarsh - CEO and Co-founder @ Dynomics - Crunchbase
He is currently working on Dynomics, a cardiovascular drug discovery company using miniature, engineered heart organoids to discover molecules to restore heart function. Jobs. ...See details»
Dynomics - Biotech Careers
Dynomics develops therapeutics to directly target the heart, using an authentic human cardiac organoid discovery engine. Business Areas: TherapeuticsSee details»
CEO & Co-founder - Dynomics - Dynomics | Forbes Technology …
Dynomics is targeting therapies to the heart and its function, to eliminate heart failure. Our discovery platform, HeartDyno™, identifies superior molecular targets and therapeutics that …See details»
Dynomics B.V. - VentureRadar
Dynomics aims to be the worldwide leader in the development of tests that provide diagnostic information on the classification of leukemia and lymphoma and information on the prognosis …See details»
Publications - Dynomics
HeartDyno® Platform. 🎉 Maturation of human cardiac organoids enables complex disease modelling and drug discovery. Pocock, M. et al. pre-print (2024). Link; Drug Screening in …See details»
7 Things Dynamic Organizations Do to Build Agility
Oct 14, 2023 By word and deed, leaders from a dynamic organization establish a management ethos of organizational agility—a set of cultural values and practices that help people work …See details»
Dynomics Therapeutics - VentureRadar
Dynomics develops molecules to restore heart function. We’ve developed HeartDyno, our cardiac organoid discovery engine, using scalable, authentic and predictive cardiac organoids that …See details»